Table 2.
Risk factors | Clinical care pathway | Extended observation period | ||||
---|---|---|---|---|---|---|
Events frequency | Observation time patient‐years | Incidence rate (95% CI) per 100 patient‐years | Events frequency | Observation time patient‐years | Incidence rate (95% CI) per 100 patient‐years | |
Total | 37 | 876 | 4.2 (3.1, 5.8) | 64 | 2231 | 2.9 (2.2, 3.7) |
Provoking risk factors (mutually exclusive groups) | ||||||
Provoked by surgery | 2 | 186 | 1.1 (0.3, 4.3) | 6 | 475 | 1.3 (0.6, 2.8) |
Non‐surgical transient risk factor | 6 | 192 | 3.1 (1.4, 7.0) | 11 | 519 | 2.1 (1.2, 3.8) |
Unprovoked VTE | 29 | 478 | 6.1 (4.2, 8.7) | 47 | 1186 | 4.0 (3.0, 5.3) |
Active cancer | 0 | 21 | N/A | 0 | 52 | N/A |
Other risk factors | ||||||
Male sex | 26 | 429 | 6.1 (4.1, 8.9) | 41 | 1042 | 3.9 (2.9, 5.3) |
Female sex | 11 | 447 | 2.5 (1.4, 4.4) | 23 | 1190 | 1.9 (1.3, 2.9) |
Pregnancy | 0 | 11 | N/A | 1 | 30 | 3.3 (0.5, 23.7) |
Contraceptive use at the time of thrombosis | 0 | 94 | N/A | 1 | 270 | 0.4 (0.0, 2.6) |
Travel | 4 | 60 | 6.6 (2.5, 17.7) | 8 | 175 | 4.6 (2.2, 3.7) |
Immobilization | 2 | 69 | 2.9 (0.7, 11.5) | 2 | 168 | 1.2 (0.3, 4.8) |
Inflammation | 8 | 117 | 6.8 (0.3, 13.7) | 15 | 317 | 4.7 (2.9, 7.9) |
Previous VTE | 2 | 175 | 1.1 (0.3, 4.6) | 10 | 492 | 2.0 (1.1, 3.8) |
Cardiovascular disease | 10 | 209 | 4.8 (2.6, 8.9) | 17 | 467 | 3.6 (2.3, 5.9) |
Heart failure | 0 | 12 | N/A | 1 | 33 | 3.0 (0.4, 21.6) |
Known thrombophilia | 0 | 36 | N/A | 1 | 91 | 1.1 (0.2, 7.8) |
Venous insufficiency | 0 | 59 | N/A | 0 | 106 | N/A |
Varicose veins | 1 | 43 | 2.3 (0.3, 16.4) | 3 | 139 | 2.2 (0.7, 6.7) |
Smoking | 7 | 200 | 3.5 (1.7, 7.4) | 13 | 524 | 2.5 (1.4, 4.3) |
Family history | 10 | 260 | 3.9 (2.1, 7.2) | 17 | 659 | 2.6 (1.6, 4.1) |
Risk factors not assessed at baseline | ||||||
Residual vein obstructiona | 12 | 270 | 4.4 (2.5, 7.8) | 22 | 689 | 3.2 (2.1, 4.8) |
Elevated Villalta scoreb ,d | 6 | 148 | 4.0 (1.8, 9.0) | 14 | 362 | 3.9 (2.3, 6.5) |
Elevated D‐dimerc | 17 | 197 | 8.6 (5.4, 13.9) | 26 | 514 | 5.1 (3.4, 7.4) |
High factor VIIIc | 9 | 120 | 7.5 (3.9, 14.5) | 17 | 329 | 5.2 (3.2, 8.3) |
Elevated CRPc | 11 | 201 | 5.5 (3.0, 9.9) | 22 | 537 | 4.1 (2.7, 6.2) |
Assessed one week before intended cessation of anticoagulation treatment.
Assessed at six months.
Assessed one month after stopping OAC.
≥5 points.